S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Immunomedics Announces Pricing of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020 (2015/2/5)|
|Immunomedics Announces Completion of Offering of $85 Million of 4.75% Convertible Senior Notes Due 2020 (2015/2/12)|
|Immunomedics Announces Proposed Offering of $85 Million of Convertible Senior Notes Due 2020 (2015/2/4)|
|Immunomedics Announces Outcome of 2014 Annual Meeting of Stockholders (2014/12/3)|
|Immunomedics to Present at 25th Annual Oppenheimer Healthcare Conference (2014/12/4)|
|Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy (2015/1/5)|
|Immunomedics Reports Expanded Phase 1/2 Trials Confirm Activity and Good Safety Profile of Sacituzumab Govitecan (Immu-132) in Patients With Advanced Triple-Negative Breast Cancer (2014/12/12)|
|Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers (2015/1/20)|
|Immunomedics Reports Preliminary Results From Pretargeted Imaging Study in Patients With Metastatic Breast Cancer (2014/12/15)|
|Immunomedics Announces Dismissal of Putative Class Action Lawsuit (2015/1/29)|
Click above to view more mutual fund data and stats for immu - Immunomedics Inc.